UNSPSC 51273604: Myrtecaine

This classification denotes an anesthetic agent with the molecular formula C17H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9902116282, chemically known as 2-(2-(6,6-dimethylbicyclo(3.1.1)hept-2-en-2-yl)ethoxy)-n,n-diethylethanamine but generally known as myrtecaine, which bears US NIH Compound Identifier 71851. European Medicines Agency schedules Myrtecaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09102MIG. The term MYRTECAINE is an International Non-Proprietary Name.

UNSPSC 51273604 Myrtecaine is a Commodity code that captures pharmaceutical products, including local anesthetic agents and related drug-delivery systems, procured by state and local health agencies and cooperative purchasing coalitions. Recent solicitations under this code show state and local governments buying naloxone (opioid overdose reversal), generic multi-source pharmaceuticals, OTC products, and drug deactivation systems to support community health, pharmacy benefit programs, and emergency response. Issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local member jurisdictions including Minnesota and Oregon). These buyers procure through a mix of competitive bidding (IFB), RFIs for market intelligence, and RFPs for multi-award pharmaceutical supply contracts with two- to three-year terms and optional renewals. Vendors must comply with FDA requirements, current Good Manufacturing Practices, Drug Supply Chain Security Act certification, E-Verify employment eligibility verification, and state-mandated insurance coverage (commercial general liability ranging to $5 million per occurrence, professional liability, and workers' compensation).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County's IFB (solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Texas HHS issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products across participating state and local facilities, with products supplied through three authorized wholesalers and contract effectiveness July 1, 2026; awards will be weighted 75 percent on price competitiveness, with smaller components on fixed pricing, administrative fee compliance, EDI capability, and format compliance.